You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SX-682

Showing 1 - 25 of 52
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Colorectal Cancer Trial run by the National Cancer Institute (NCI) (Retifanlimab, Therapeutic CEA, Brachyury and MUC1

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Dec 4, 2023

Pancreatic Cancer Trial in Baltimore (Tislelizumab, SX-682)

Not yet recruiting
  • Pancreatic Cancer
  • Baltimore, Maryland
    Johns Hopkins SKCCC
Jan 23, 2023

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 Trial in

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +3 more
  • Biopsy
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 9, 2023

Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma Trial in Houston (CXCR1/2

Recruiting
  • Metastatic Colon Adenocarcinoma
  • +20 more
  • CXCR1/2 Inhibitor SX-682
  • Nivolumab
  • Houston, Texas
    M D Anderson Cancer Center
Aug 17, 2022

Metastatic Cancer, Solid Tumors Trial run by the NCI (SX-682, M7824, MVA-BN-CV301)

Active, not recruiting
  • Metastatic Cancer
  • Solid Tumors
  • SX-682
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 11, 2022

MDS Trial in Orlando, Tampa, Baltimore (SX-682)

Recruiting
  • Myelodysplastic Syndromes
  • SX-682
  • Orlando, Florida
  • +2 more
Feb 18, 2022

Melanoma Stage III, Melanoma Stage IV Trial in Boston, Rochester, Houston (SX-682, Pembrolizumab)

Recruiting
  • Melanoma Stage III
  • Melanoma Stage IV
  • SX-682
  • Pembrolizumab
  • Boston, Massachusetts
  • +4 more
Jan 26, 2022

Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Trial in Rochester (SX-682, Nivolumab Injectable Product)

Recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Pancreatic Cancer
  • SX-682
  • Nivolumab Injectable Product
  • Rochester, New York
    University of Rochester
Dec 14, 2021

Assessment of a New Acceleromyograph, Neuromuscular Block Trial in Dormagen (acceleromyography)

Recruiting
  • Assessment of a New Acceleromyograph
  • Neuromuscular Block
  • acceleromyography
  • Dormagen, Germany
    KKH Dormagen
Mar 30, 2022

Gastrointestinal Tumors Trial in Houston

Recruiting
  • Gastrointestinal Neoplasms
    • Houston, Texas
      Baylor College of Medicine
    Jun 10, 2022

    Diabetes, Type 2 Trial (Near-infrared (NIR))

    Not yet recruiting
    • Diabetes Mellitus, Type 2
    • Near-infrared (NIR)
    • (no location specified)
    Jul 25, 2022

    Neuromuscular Blockade Trial in Geneva, Lugano (TOF Watch SX)

    Terminated
    • Neuromuscular Blockade
    • TOF Watch SX
    • Geneva, Canton Of Geneva, Switzerland
    • +1 more
    Jan 10, 2022

    Agreement Between Standard and Continuous Wireless Vital Sign

    Completed
    • Postoperative Patients
      • Copenhagen, Denmark
        Department of Anesthesiology, Center for Cancer and Organ Diseas
      Apr 12, 2022

      Obesity Trial in Paris (the sleeve gastroplasty with the endoscopic system Overstich SX)

      Recruiting
      • Obesity
      • the sleeve gastroplasty with the endoscopic system Overstich SX
      • Paris, France
        Clinique Du Trocadero
      Nov 18, 2021

      A Comparison Between TOF Watch® SX and Tetragraph®

      Completed
      • Neuromuscular Blockade
      • Neuromuscular Monitoring
      • Tetragraph® (Senzime, Uppsala, Sweden)
      • TOF Watch® SX (Organon Teknika B.V., Boxtel, Holland)
      • Milan, Mi, Italy
        Fondazione IRCCS Istituto Nazionale dei Tumori
      Jun 23, 2021

      Acceleromyography- and Electromyography-based Neuromuscular

      Not yet recruiting
      • Neuromuscular Blockade
      • TOF-Watch®；DELSYS® Wireless surface EMG
      • Wuhan, Hubei, China
        Department of Anaesthesiology, Tongji Hospital of Tongji Medical
      Dec 15, 2022

      Nasopharyngeal Carcinoma, Toripalimab, Recurrent Nasopharyngeal Squamous Cell Carcinoma Trial in Nanning (Toripalimab)

      Recruiting
      • Nasopharyngeal Carcinoma
      • +2 more
      • Nanning, Guangxi, China
        Guangxi Medical University Cancer Hospital
      Aug 16, 2021

      Ovarian Cancer Trial in Milwaukee (Pembrolizumab, Carboplatin, Paclitaxel)

      Active, not recruiting
      • Ovarian Cancer
      • Milwaukee, Wisconsin
        Medical College of Wisconsin and Froedtert Hospital
      Apr 7, 2022

      TOFscan and TOF-Watch SX in Pediatric Neuromuscular Function

      Completed
      • Neuromuscular Blockade
      • TOFscan
      • Seoul, Korea, Republic of
        Seoul National University Hospital
      Apr 15, 2020

      Carpal Tunnel Trial run by the (USCTR, mOCTR)

      Recruiting
      • Carpal Tunnel
      • USCTR
      • mOCTR
      • Bethesda, Maryland
        Walter Reed National Military Medical Center
      May 18, 2021

      Post-Traumatic Stress Disorder, Stress Disorders, Post-Traumatic Trial in Chiba, Tokyo (paroxetine, )

      Terminated
      Has Results
      • Post-Traumatic Stress Disorder
      • Stress Disorders, Post-Traumatic
      • Chiba, Japan
      • +8 more
      Nov 20, 2020

      Crohn Disease Trial in Worldwide (Ozanimod)

      Recruiting
      • Crohn Disease
      • Peoria, Arizona
      • +1232 more
      Jan 9, 2023

      General Anesthesia Trial in Poitiers (Isometric Trumb Force handle)

      Completed
      • General Anesthesia
      • Isometric Trumb Force handle
      • Poitiers, France
        Chu de Poitiers
      Oct 30, 2019

      Influenza Trial in Worldwide (Candidate Influenza Vaccine GSK1247446A - 3 different formulations, Fluarix TM)

      Completed
      Has Results
      • Influenza
      • Candidate Influenza Vaccine GSK1247446A - 3 different formulations
      • Fluarix TM
      • Tartu, Estonia
      • +45 more
      May 9, 2018

      Rare Diseases, Orphan Diseases Trial in Germany (dual expert guidance structure)

      Unknown status
      • Rare Diseases
      • Orphan Diseases
      • dual expert guidance structure
      • Würzburg, Bavaria, Germany
      • +11 more
      Sep 23, 2020